Press Release Apr 01 2022
Filed with NSE · · 3 pages · English
Summary by 6ix AI
The press release highlights that the vaccine's safety and efficacy data were peer-reviewed and confirms the trial's compliance with global standards. Dr. Sharvil Patel, the Managing Director, expressed satisfaction with the publication, emphasizing adherence to stringent clinical trial practices.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 21 2022
- Press Release Mar 14 2022
- Press Release Mar 09 2022
- Press Release Mar 08 2022
- Press Release Mar 07 2022
Later from Zydus Lifesciences
- Press Release Apr 13 2022
- Press Release Apr 18 2022
- Press Release Apr 25 2022
- Press Release Apr 26 2022
- Press Release May 03 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences